USACIG to Enter Nicotine Medical Research for Treatment of Parkinson's Disease; Hop-on, Inc. Named to Be Exclusive Agent for FD
IRVINE, CA--(Marketwire - December 16, 2009) - USACIG, Inc. and Hop-on, Inc. (
Peter Michaels, CEO of Hop-on, states, "Studies on nicotine through cigarette use have proven to delay the onset of Parkinson's disease. Nicotine in its natural state removed from cigarettes is safe and non-toxic. USACIG nicotine water technology delivers pure organic and non-toxic nicotine without harmful chemicals. While nicotine has had an image problem due to its association with smoking, there is much excitement about nicotine's potential to prevent and help with a number of medical issues. We are very excited about being USACIG's exclusive agent for FDA submission. USACIG will be working on the funding for clinical studies."
The Parkinson's Institute and Clinical Center is also continuing research showing that intermittent nicotine treatment reduces medication-induced dyskinesias by as much as 50% in models of Parkinson's disease. Lead by senior research scientist, Maryka Quik, Ph.D.
About USACIG, Inc.
USACIG, Inc. is a US-based manufacturer of "The Electric Cigarette and The Electric Cigar"™. USACIG manufactures its cartridges in the United States and the electronics are manufactured in China. USACIG also has US-based doctors on its board to supervise any medical related issues or opportunities. For more information, visit [ www.USACIG.com ]
About Hop-on, Inc.
Hop-on, Inc. (
Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All Statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.